The FDA granted Viracta Therapeutics orphan status for its potential treatment of nasopharyngeal carcinoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VIRX:
- Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
- Viracta Therapeutics announces interim data from Phase 1b/2 trial of nana-val
- Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Viracta Therapeutics reports Q3 EPS (33c), consensus (30c)
- Viracta Therapeutics to Present at Upcoming Investor Conferences